Gilead Sciences announced that the FDA has approved Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate), a single tablet HIV-1 regimen for use in certain virologically suppressed (HIV RNA <50 copies/mL) adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen.

RELATED: Infectious Disease Resource Center

The approval was based on data from the Phase 3 SPIRIT (Study 106) clinical trial, a randomized, open-label study in virologically suppressed patients who were taking multi-tablet HIV therapy containing a ritonavir-boosted protease inhibitor (PI) who either switched to Complera or remained on their PI-based regimen. The study showed that, after 48 weeks of treatment with Complera, 89% (n=283/317) of switch patients had viral load <50 copies/mL, compared to 90% (143/159) of patients who remained on a PI-regimen for 24 weeks.

Complera is already approved for use as a complete regimen to treat HIV-1 infection in antiretroviral treatment-naive adults with HIV-1 RNA ≤100,000 copies/mL at the start of therapy. The product combines Gilead’s Truvada (emtricitabine and tenofovir disoproxil fumarate), which itself is a fixed-dose combination of two HIV medicines, with rilpivirine (EdurantJanssen Therapeutics).

Continue Reading

Complera contains emtricitabine 200mg, rilpivirine 25mg, and tenofovir disoproxil fumarate 300mg per tablet.

For more information call (800) GILEAD-5 or visit